5 Minutes Read

US ends COVID-19 vaccine requirement for international travellers effective May 11

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The Biden-Harris Administration announced on May 2 that the requirements will end on May 11, the same day that the COVID-19 public health emergency ends. Further details related to ending these requirements will soon be provided.

The United States government has announced that it is ending its COVID-19 vaccine requirements for international travellers, effective today, May 11. This comes as the COVID-19 public health emergency in the nation also comes to an end on Thursday.

US President Joe Biden’s administration had initially implemented vaccination requirements for federal employees, contractors and international air travellers in a bid to promote the health and safety of individuals and the efficiency of workplaces.

ALSO READ | COVID-19 | India reports 7,533 fresh infections and 44 deaths

The Biden-Harris Administration announced on May 2 that the requirements will end on May 11, the same day that the COVID-19 public health emergency ends. Further details related to ending these requirements will soon be provided.

The announcement followed a successful vaccination campaign that saw almost 270 million Americans receive at least one dose of the COVID-19 vaccine.

The vaccination requirements helped ensure the safety of workers in critical workforces, such as healthcare and education, and protected the populations they serve, enabling them to provide services without disruptions to operations.

The Federal government implemented requirements for its workforce in a way that increased vaccination to achieve 98 percent compliance, reflecting employees who had received at least one dose of a vaccine or had a pending or approved exception or extension request filed by January 2022.

ALSO READ | Why airline tickets are still so expensive and likely to remain that way

The administration also put in place vaccination requirements for certain international travellers to slow the spread of new variants entering the country and to allow the healthcare system time to manage access to care if faced with an increase in cases and hospitalizations.

The announcement stated that vaccination remains one of the most important tools in advancing the health and safety of employees and promoting the efficiency of workplaces, but the decision to end the vaccination requirements for certain groups was made as the country is now in a different phase of its response, and the measures are no longer necessary.

The announcement also included HHS and DHS’s decision to start the process to end their vaccination requirements for Head Start educators, CMS-certified healthcare facilities, and certain noncitizens at the land border. The administration will provide further details in the coming days related to ending these requirements.

ALSO READ | Flight cancelled or delayed? Know your rights as a passenger

As of May 2, over 147 million people in the United States have been fully vaccinated against COVID-19, according to the Centers for Disease Control and Prevention (CDC).

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Time for India to update COVID-19 vaccine against latest variant: Former AIIMS director

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The coronavirus has mutated significantly, with new strains such as alpha, beta, delta, and omicron emerging.

India may have to update its COVID-19 booster shots with the latest strain of the coronavirus, similar to flu vaccines, according to renowned pulmonologist and former AIIMS director Dr Randeep Guleria.

Speaking with News18.com, Guleria noted that the vaccines currently being used in India are based on the Wuhan strain or the strain that was circulating in December 2019, while the virus has since mutated significantly, with new strains such as alpha, beta, delta, and omicron emerging.

He warned that the efficacy of the vaccines against the latest strains may have declined significantly, and pointed out that countries such as the US and UK have already updated their vaccines to include both old and new strains. Flu vaccines are updated annually against the latest strain in the environment.

ALSO READ | COVID-19 LIVE update: Active cases jumps to over 37,000, second day of mock drills today

“By now, the strain of the virus has changed and evolved dramatically. From alpha, beta, delta to now omicron and its sub-lineages, the virus has mutated long back,” Guleria said.

Guleria, who is also the president of All India Institute of Medical Sciences (AIIMS) Bilaspur, cautioned that although Indian vaccines reported efficacy of 80-90 percent during trials, the effectiveness of these vaccines against the latest strain might have decreased significantly.

He further noted that the new strain of the virus has evolved dramatically, and flu vaccines are updated every year to incorporate the latest strain.

As India records a rise in COVID-19 cases, Guleria advised people to exercise caution, especially vulnerable populations such as the elderly and those with co-morbid conditions. He noted, however, that there is no need to create panic, just be more cautious.

According to government data, India reported 5,676 new COVID-19 cases in 24 hours, taking the active caseload to 37,093. The daily positivity rate stands at 2.88 percent, while the weekly positivity rate is at 3.81 percent.

ALSO READ | Covovax gets government’s nod as heterologous COVID-19 booster on CoWIN

Guleria attributed the surge in cases to a lack of COVID-appropriate behaviour among the public, mutation in the virus making it more infectious and changes in weather leading to more viral infections.

While Guleria acknowledged that the new XBB.1.16 variant could be one of the reasons driving the recent surge, he emphasized that there is no need to panic.

“If cases of infection will increase, chances of these vulnerable people getting the disease also increases,” he warned.

ALSO READ | New XBB.1.16 COVID variant behind spike in India’s coronavirus cases? What we know so far

He suggested that updating vaccines with the latest strain could be a possible solution, but more data needs to be analyzed to determine its efficacy.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

From plane to truck, car, boat & finally on foot, how Covid-19 vaccine reached remotest parts of India

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Detailing the action plan during the pandemic, Prime Minister Narendra Modi, in ‘The Vial – India’s Vaccine Story’ — History TV18’s new documentary on the country’s Covid-19 vaccine journey — said airplanes would fly across the country day and night carrying vaccines. “It took a lot of effort. We put a lot of other government work on hold,” he said

India’s diversity has always been its crown jewel. Celebrated for its vast and different terrains, the country, however, faced a mega challenge when the Covid-19 pandemic hit and the need of the hour was to vaccinate a huge population in the remotest corners.

Detailing the action plan during the pandemic, Prime Minister Narendra Modi, in ‘The Vial – India’s Vaccine Story’ — History TV18’s new documentary on the country’s Covid-19 vaccine journey — said airplanes would fly across the country day and night carrying vaccines. “It took a lot of effort. We put a lot of other government work on hold,” he said.

In an interesting case study shared in the documentary, which aired at 8pm on Friday, actor and narrator Manoj Bajpayee explained how the vaccines reached a small village in Mizoram.

To reach Nunsury village, the vaccines started their 1500-kilometre ‘yatra’ from Pune where they were manufactured. They first reached Kolkata’s regional storage centre from where they were transported to Aizawl. The journey then continued via truck to Lunglei, in a car till Tlabung and finally via a boat to Nunsury. The challenge, however, was not over yet.

Also Read: ‘It Would be Foolishness to Assume…’ Know the first thought in PM Modi’s mind as Covid-19 engulfed the world

Healthcare workers and vaccinators then set off on foot to ensure not even one villager was left behind in the world’s biggest inoculation drive.

Marrying technology with a spirit to eliminate the virus from the country also led to ingenious solutions. It was decided to use drones to deliver vaccines in the remotest parts of the North-eastern states of Nagaland and Manipur.
Dr Sumit Aggarwal, a scientist with the Indian Council of Medical Research (ICMR), said: “The motto was that if we can deliver these vaccines by drone to these remote areas, then we can deliver in any part of India.”

It was the grit of frontline workers and scientists as well as a desire to save mankind that gave rise to India’s vaccination feat which is praised the world over.

A look at ‘The Vial – India’s Vaccine Story’

The brand new documentary on the country’s incredible Covid-19 vaccine journey brings to life the inside story of what went into producing the Covid-19 vaccine vial, revealing the country’s success in developing, manufacturing and delivering the vaccine in unprecedented timelines.

The 60-minute documentary is the first of its kind to feature PM Modi where he speaks in detail about India’s victory over the coronavirus pandemic.

‘The Vial’ takes a closer look at some of the case studies that put the spotlight on the determination of the Indian government and health workers in making vaccines accessible to people even in the remotest areas, braving harsh terrain and landscapes.

Today, a majority of India’s 1.3 billion people have received at least one round of the vaccine — a herculean task, given the diversity of the country. India also set an example for the world with the Vaccine Maitri initiative through which 232.43 million doses of the Covid-19 vaccine were provided across 100 countries.

Also Read: Not just tough terrain, frontline workers fought mindsets for Covid jab | History TV18 Documentary

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

‘It Would be Foolishness to Assume…’ Know the first thought in PM Modi’s mind as Covid-19 engulfed the world

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

For Prime Minister Narendra Modi, Covid-19 was never an isolated occurrence. In his first-ever detailed assessment of the pandemic that broke the world’s back, PM Modi, who features in ‘The Vial – India’s Vaccine Story’ — History TV18’s new documentary on the country’s Covid-19 vaccine journey — said the severity of the pandemic across the …

For Prime Minister Narendra Modi, Covid-19 was never an isolated occurrence. In his first-ever detailed assessment of the pandemic that broke the world’s back, PM Modi, who features in ‘The Vial – India’s Vaccine Story’History TV18’s new documentary on the country’s Covid-19 vaccine journey — said the severity of the pandemic across the globe was becoming visible as images of overflowing hospitals and dead bodies came out.

“It is true that initially, India was insulated from the virus but today, the world is extremely small, inter-related, interconnected and inter-dependent. The first thought in my mind was that it would be foolishness to assume that the pandemic would be limited to the rest of the world and never hit India,” the prime minister said.

Talking about the tough decision of imposing a nation-wide lockdown to curb the spread of the virus, PM Modi said: “The only way to escape the pandemic is to save yourself. ‘Jaan hai toh jahaan hai’. I was able to educate people about this.”

Also Read: ‘Today, I am satisfied’: In a first, PM Modi talks about leading battle against Covid, rush to bring vaccine

The prime minister admitted that even though the country knew that economic woes would follow and supply chains would be affected, people followed the Janta curfew. “It is a wonder for the world that a country as huge as India managed a lockdown of so many days. No other country in the world could take its citizens in that direction,” the prime minister said.

History TV18’s 60-minute documentary, narrated by actor Manoj Bajpayee, details the story of India’s grit in the face of an invisible enemy and how the country, led by PM Modi, developed, manufactured and delivered the Covid-19 vaccine in unprecedented timelines.

‘The Vial – India’s Vaccine Story’, which premieres on History TV18 at 8pm on Friday, has many firsts and several untold stories that make it a must-watch. It also features interviews of vaccine manufacturers — Adar Poonawala, CEO of Serum Institute of India, and Dr Krishna Ella, chairman of Bharat Biotech — among others apart from detailing India’s initiatives such as the CoWIN App and Vaccine Maitri to help other countries with the vaccine.

Also Read: Not just tough terrain, frontline workers fought mindsets for Covid jab | History TV18 Documentary

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

‘The Vial’ trailer out: Manoj Bajpayee narrates History TV18’s documentary on India’s COVID-19 vaccine journey

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

A majority of India’s 1.3 billion people have received at least one round of the vaccine. India also set an example for the world with the Vaccine Maitri initiative through which 232.43 million doses of the vaccine were provided across 100 countries

India’s Covid-19 vaccination programme has proven to be the world’s largest but how did the nation, led by Prime Minister Narendra Modi, embark on this journey? To find out the details of a historic and unprecedented battle, check out History TV18’s documentary titled “The Vial – India’s Vaccine Story” on March 24, 2023, at 8 pm.

‘The Vial’ brings to life the inside story of what went into producing the Covid-19 vaccine vial, unfolding the story behind India’s success in developing, manufacturing and delivering the Covid-19 vaccine in unprecedented timelines.

The 60-minute documentary is narrated by renowned actor Manoj Bajpayee. This is the first documentary to feature PM Modi where he speaks in detail about India’s victory over the coronavirus pandemic. History TV18 has released a trailer of the documentary which also features Serum Institute of India CEO Adar Poonawalla, Microsoft Founder Bill Gates, Narayana Hrudayalaya’s Dr Devi Shetty and Bharat Biotech’s Dr Krishna Ella among others.

“The Vial” also chronicles the development of the Covishield vaccine — From isolation of the strain at Pune’s National Institute of Virology to manufacturing billions of vials of two of the world’s most effective vaccine candidates in record time to cater to the country’s massive population.

Also read: India completes 2 years of COVID vaccination — the success story so far

Speaking to Network18, Manoj Bajpayee said: “India’s Covid-19 vaccine story is a remarkable accomplishment for the country and, as Indians, we all should be aware and proud of it. This film is a tribute to our healthcare professionals and frontline workers who produced the vaccines in unprecedented timelines and executed the vaccination drive, despite several challenges. They are the reason why we are stepping out of our homes confidently today.”

‘The Vial’ takes a closer look at some of the case studies that put the spotlight on the determination of the Indian government and health workers in making vaccines accessible to people even in the remotest areas, braving harsh terrain and landscapes.

Today, a majority of India’s 1.3 billion people have received at least one round of the vaccine — a herculean task, given the diversity of the country. India also set an example for the world with the Vaccine Maitri initiative through which 232.43 million doses of the Covid-19 vaccine were provided across 100 countries.

Also read: AstraZeneca’s global chairman reflects on 3 billion COVID shots and what’s next

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Novavax needs 6 months to produce annual COVID shots that match new variants

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The FDA is seeking recommendations from its panel of external experts on adopting an annual COVID shot for the United States and the process for choosing the vaccine’s targets each year.

Novavax Inc said on Thursday it would require six months to produce a COVID-19 vaccine designed to match whichever coronavirus variants are circulating for an annual immunization program each fall season in the United States.

The company suggested that the U.S. Food and Drug Administration select the prevalent variant of coronavirus in the first quarter each year, similar to the model employed to choose the composition for annual flu shots.

The FDA in documents released on Monday proposed June for deciding on an annual COVID shot’s make-up.

Novavax’s protein-based vaccine requires manufacturing changes that take longer to implement than the messenger RNA vaccines produced by Pfizer Inc/BioNTech SE and Moderna Inc. It took those companies about three months to produce the currently available boosters updated to target newer Omicron subvariants.

“We recognize the tension between selecting a strain as late as possible to increase the likelihood of recommending a matching strain versus providing adequate time to ensure vaccine availability,” Novavax Chief Medical Officer Filip Dubovsky said during a presentation for the FDA’s vaccine advisory panel.

The FDA is seeking recommendations from its panel of external experts on adopting an annual COVID shot for the United States and the process for choosing the vaccine’s targets each year.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Pain in eyes, blurred vision after COVID-19 vaccine? RTI reply reveals multiple side-effects of jabs

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

As per an RTI reply, some of the side-effects of COVID-19 include: Shortness of breath, chest pain, pain in limbs or swelling on pressing of calf/arms, pain in eyes, blurred vision or diplopia, change in mental status, encephalopathy or depressed level of consciousness.

It’s official. The government’s two top watchdogs have admitted to ‘multiple side-effects’ of COVID-19 vaccines that were jabbed in over a billion Indians in the past more than two years.

The startling revelations are made by the Indian Council of Medical Research (ICMR) and Central Drugs Standard Control Organisation (CDSCO) in an RTI reply to Pune businessman Prafful Sarda.

ALSO READ | India completes 2 years of COVID vaccination — the success story so far

India has permitted AstraZenaca and Serum Institute of India, Pune’s ‘Covishield’ and SII’s own ‘Covovax’; vaccines of three Hyderabad-based companies — the government-run Bharat Biotech Ltd.’s Covaxin, Dr. Reddy’s Lab imported Sputnik V, Biological E. Ltd.’s CorBEvax, and later, Cadila Healthcare Ltd., Ahmedabad’s ZyCov-D only for teenagers (12-17 age).

ALSO READ | Omicron sub-variant XBB.1.5 explained — transmissibility, severity, immune evasive effects and more

In a specific query by Sarda on the side-effects of all these jabs, the ICMR’S PIO Dr. Leyanna Susan George and CDSCO’s PIO Sushanta Sarkar, have cited a plethora of ramifications arising out of all these vaccines comprising their FAQs.

Covishield takes the lion’s share of its after-effects on the jabbed janta — injection site tenderness or pain, multiple red spots or bruises beyond the injected site, persistent vomiting without reasons, severe or persistent abdominal pains or headaches with or without vomiting, shortness of breath, chest pains, pain in limbs or swelling on pressing of calf/arms, weakness/paralysis of limbs of any particular side or parts of the body, including cranial nerves, unprecedented seizures, pain in eyes, blurred vision or diplopia, change in mental status, encephalopathy or depressed level of consciousness.

ALSO READ | A factcheck on COVID-19 symptoms — Does muscle pain, dry mouth, skipping meals indicate infection

Covovax side-effects are injection site pain/tenderness/induration, fatigue, malaise, headaches, fever, soreness of muscles, joint pains, nausea of vomiting, chills, body-ache or extreme pain in limbs, Asthenia (weakness or lack of energy), Injection site pruritus (itching, rash, red skin, hives), enlarged lymph nodes, back pains, and rarely dizziness or drowsiness.

Covaxin displays mild symptoms AEFIs like injection site pain/swelling, headaches, fatigue, fever, bodyache, abdominal pain, nausea, vomiting, dizziness, giddiness, tremors, sweating, cold and cough.

Sputnik V manifests with chills, fever, arthralgia, myalgia, asthenia, headaches, general discomfort, injection site pain/swelling/hyperaemia, or nausea, dyspepsia, loss of appetite, or occasional enlarged regional lymph nodes.

Corbevax shows effects like fever/pyrexia, headaches, fatigue, body pains, myalgia, nausea, or arthralgia, urticaria, chills, lethargy, besides injection site pain/erythema, swelling, rash, pruritis or irritation.

“The replies by ICMR-CDSCO are blatantly shocking. Though the government has declared that “vaccination is totally voluntary”, why was the compulsion created indirectly by barring people from travelling in buses, trains, flights, inter-state movements, going out to hotels, restaurants, multiplexes, malls, etc. This trapped more and more panicked people into getting themselves jabbed without knowing the after-effects,” said Sarda sharply.

He urged the government to release data on whether adequate publicity on all these possible side-effects was done through media, by hospitals, vaccination centres, and if the health ministry initiated any public safety campaigns for the gullible masses, now that vaccine-related deaths are being reported in India and worldwide.

Sarda cited how India had donated crores of free vaccines — leading to an uproar in 2021 — to many poor countries worldwide and questioned whether all the potential complications of the jabs were brought to the notice of the people in those nations.

“All the global agencies have set the benchmark that only those vaccine candidates that show an efficacy of at least 50-60 per cent will be considered. Most of the vaccines have shown an efficacy of 70-90 per cent within the short period of two or three months of observation. More than 100 crore people have received at least a single dose of COVID-19 vaccine and the proportion of side effects is very low,” the government has assured.

After the initial mass-vaccinations, mostly free was completed, from August 2022, the government has permitted conditional market sales of Covishield and Covaxin but the others — Sputnik V and CorBEvax — remain specifically for “restricted emergency use”, as per the RTI.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Imports of COVID-19 vaccines exempted from customs duty till March 31

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The government has exempted customs duty on imports of Covid19 vaccines till March 31, 2023, in a bid to ensure domestic availability amid fears of a surge in coronavirus infections.

The government has exempted customs duty on imports of COVID-19 vaccines till March 31, 2023, in a bid to ensure domestic availability amid fears of a surge in coronavirus infections.

In a notification, the Central Board of Indirect Taxes and Customs (CBIC) said COVID vaccines, when imported into India by central government or state governments, would be exempt from the whole of customs duty from January 14, 2023, till March 31, 2023.

The government had, in April 2021, first exempted COVID-19 vaccines from 10 percent customs duty. The exemption was extended several times till June 2022.

Also Read: Chinese city dwellers head to hometowns as holidays raise COVID stakes

With new variants causing a significant rise in daily caseload in certain countries, including neighbouring China, the government had re-introduced certain precautionary measures, like random passenger testing at airports and genome sequencing, to check COVID spread in India.

Currently, COVID vaccines administered in India include Covishield, Covaxin, Sputnik V, Corbevax and Covovax.

Also Read: WHO issues new COVID-19 guidelines | Here’s what you need to know

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

SII seeks drug regulator’s approval for market authorisation of its Covid vaccine as booster dose

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Prakash Kumar Singh, director of government and regulatory affairs, SII, submitted a market authorisation application for the heterologous booster dose of Covovax to the drugs controller general of India (DCGI) on October 17.

The Serum Institute of India (SII) has sought the drug regulator’s approval for market authorisation of its COVID-19 vaccine Covovax as a booster dose for those aged 18 years and above who have been administered two doses of Covishield or Covaxin, official sources said on Thursday.

Prakash Kumar Singh, director of government and regulatory affairs, SII, submitted a market authorisation application for the heterologous booster dose of Covovax to the drugs controller general of India (DCGI) on October 17.

It has been learnt that the DCGI’s office had raised a few queries, after which Singh submitted a reply, mentioning about the current emerging situation caused by a new coronavirus variant.

Also Read: Air travel guidelines amid COVID surge: Health ministry could mandate ‘Air Suvidha’ form, vaccination again

Covovax was approved by the DCGI for restricted emergency use in children aged seven to 11 years in June. The DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, and for those in the 12-17 age group, subject to certain conditions, on March 9.

Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation.

It was granted an emergency-use listing by the World Health Organization (WHO) on December 2017, 2020. In August 2020, US-based vaccine maker Novavax Inc. announced a licence agreement with the SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in India and low-and-middle-income countries.

Also Read: Omicron new variant in India: What are high-risk states up to

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Omicron BF.7 Highlights: PM Modi holds review meeting, new travel guidelines issued

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

COVID News Live Updates: Union Health Minister Mansukh Mandaviya said on Thursday that in the wake of festive and new year season, states are advised to make sure people wear masks, use sanitisers and maintain social distancing. They have also been directed to increasing awareness about precautionary doses. Prime Minister Narendra Modi also held a high-level meeting on Thursday. Follow LIVE updates on COVID-19 situation in India here.

Union Health Minister Mansukh Mandaviya said on Thursday that in the wake of festive and new year season, states are advised to make sure people wear masks, use sanitisers and maintain social distancing. They have also been directed to increasing awareness about precautionary doses. Prime Minister Narendra Modi also held a high-level meeting on Thursday. Follow LIVE updates on COVID-19 situation in India here.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?